Elexacaftor + tezacaftor + ivacaftor
1 paper1 finding
PubChem 134587348PubChem 46199646PubChem 16220172ChEBI 234518ChEBI 234517ChEBI 66901
- 1 lab in 1 country
- Funders: Canada Research Chairs and 3 more
- Human trial1
Outcomes
1GrimAge2
downin humans1
1 study
GrimAge2
downin humans1
Elexacaftor + tezacaftor + ivacaftor decreases GrimAge2 in humans (from 1.92 years to -1.70 years (p=0.008)).
“DNAmGrimAge2 age acceleration decreased after ETI treatment, from a median of 1.92 years before treatment to -1.70 years after 1 year (p=0.008).”
Human trial1 yearn = 8
bioRxiv18 Sep 2026Preprint
Latest
1 in 12 monthsbioRxiv
Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis
Preprint: non-randomised trial in 8 peopleInterventions